Kazia Therapeutics Limited (NASDAQ:KZIA – Free Report)’s stock is scheduled to reverse split before the market opens on Monday, October 28th. The 1-10 reverse split was announced on Tuesday, October 15th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, October 25th.
Kazia Therapeutics Trading Up 1.9 %
Kazia Therapeutics stock opened at $0.58 on Thursday. The firm’s 50 day moving average price is $0.40 and its two-hundred day moving average price is $0.36. Kazia Therapeutics has a twelve month low of $0.19 and a twelve month high of $1.58.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Kazia Therapeutics in a research note on Friday, July 12th.
Kazia Therapeutics Company Profile
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.
Featured Articles
- Five stocks we like better than Kazia Therapeutics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- 3 Warren Buffett Stocks to Buy Now
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Upcoming IPO Stock Lockup Period, Explained
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
